HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention

Key Points

Key points are not available for this paper at this time.

Abstract

Plasma concentrations of tenofovir consistent with daily dosing were highly predictive of protection from HIV acquisition. Most of those who took PrEP seemed to have high and consistent adherence.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Donnell et al. (Wed,) studied this question.

synapsesocial.com/papers/69df575d915fa04953614a74 https://doi.org/https://doi.org/10.1097/qai.0000000000000172

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

How Treatment Partners Help: Social Analysis of an African Adherence Support Intervention

2011 · 68 citations